Adeno-associated virus (AAV)-based gene therapies have shown promise as novel treatments for rare genetic disorders such as hemophilia A and spinal muscular atrophy. However, cellular immune responses mediated by cytotoxic (CD8+) and helper (CD4+) T cells may target vector-transduced cells as well as healthy immune cells, impacting safety and efficacy. In this study, we describe the optimization and reproducibility of interferon-γ (IFNγ)–based and interleukin-2 (IL-2)–based enzyme-linked immunosorbent spot (ELISpot) assays for measuring T cell responses against AAV peptide antigens. For method optimization, peripheral blood mononuclear cells (PBMCs) were isolated from healthy human donors and stimulated with commercially available major histocompatibility complex (MHC) class I or II–specific peptides as positive controls. Peptide pools were designed from published AAV8 and AAV9 capsid protein sequences and then used to assess the presence of AAV-specific T cell responses. Our results demonstrate a measurable increase in IFNγ and IL-2–producing cells after AAV peptide presentation. Furthermore, there was an observed difference in the magnitude and specificity of response to peptide pools based on AAV serotype and donor. Finally, using individual peptides, we identified a region of the AAV9 capsid protein that can elicit an immunogenic response. This work shows the applicability of ELISpot in assessing anti-AAV immune responses and provides insight into how novel recombinant AAV vectors could be designed to reduce immunogenic potential.
Get full access to this article
View all access options for this article.
References
1.
AthanasopoulosT, FabbS, DicksonG. Gene therapy vectors based on adeno-associated virus: Characteristics and applications to acquired and inherited diseases (review). Int J Mol Med, 2000; 6(4):363–375; doi: 10.3892/ijmm.6.4.363
2.
ZhaoN, LiuD-P, LiangC-C. Hot topics in adeno-associated virus as a gene transfer vector. Mol Biotechnol, 2001; 19(3):229–237; doi: 10.1385/mb:19:3:229
HareendranS, BalakrishnanB, SenD, et al.Adeno-associated virus (AAV) vectors in gene therapy: Immune challenges and strategies to circumvent them. Rev Med Virol, 2013; 23(6):399–413; doi: 10.1002/rmv.1762
5.
LargeEE, SilveriaMA, ZaneGM, et al.Adeno-associated virus (AAV) gene delivery: Dissecting molecular interactions upon cell entry. Viruses, 2021; 13(7):1336; doi: 10.3390/v13071336
6.
KayMA, GloriosoJC, NaldiniL. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med, 2001; 7(1):33–40; doi: 10.1038/83324
7.
RaptiK, Louis-JeuneV, KohlbrennerE, et al.Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther, 2012; 20(1):73–83; doi: 10.1038/mt.2011.177
8.
YangL, XiaoX. Creation of a cardiotropic adeno-associated virus: The story of viral directed evolution. Virol J, 2013; 10(1):50; doi: 10.1186/1743-422x-10-50
9.
Petrs-SilvaH, DinculescuA, LiQ, et al.High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther, 2009; 17(3):463–471; doi: 10.1038/mt.2008.269
10.
Colón-ThilletR, JeromeKR, StoneD. Optimization of AAV vectors to target persistent viral reservoirs. Virol J, 2021; 18(1):85; doi: 10.1186/s12985-021-01555-7
11.
HammondSL, LeekAN, RichmanEH, et al.Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection. PLoS One, 2017; 12(12):e0188830; doi: 10.1371/journal.pone.0188830
12.
Colon-MoranW, BaerA, LamtureG, et al.A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity. Gene Ther, 2022; 29(10–11):616–623; doi: 10.1038/s41434-021-00302-5
13.
BretonC, FurmanakT, AvittoAN, et al.Increasing the specificity of AAV-based gene editing through self-targeting and short-promoter strategies. Mol Ther, 2021; 29(3):1047–1056; doi: 10.1016/j.ymthe.2020.12.028
14.
TongJG, EvansAC, HoML, et al.Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform. J Control Release, 2019; 307:292–301; doi: 10.1016/j.jconrel.2019.06.034
15.
ChirmuleN, PropertKJ, MagosinSA, et al.Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther, 1999; 6(9):1574–1583; doi: 10.1038/sj.gt.3300994
16.
HuiDJ, EdmonsonSC, PodsakoffGM, et al.AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. Mol Ther Methods Clin Dev, 2015; 2:15029; doi: 10.1038/mtm.2015.29
17.
LiuQ, HuangW, ZhangH, et al.Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: Implications for gene therapy using AAV vectors. Gene Ther, 2014; 21(8):732–738; doi: 10.1038/gt.2014.47
18.
CalcedoR, WilsonJM. Humoral immune response to AAV. Front Immunol, 2013; 4:341; doi: 10.3389/fimmu.2013.00341
19.
MingozziF, HighKA. Immune responses to AAV in clinical trials. Curr Gene Ther, 2011; 11(4):321–330; doi: 10.2174/156652311796150354
20.
KarlssonAC, MartinJN, YoungerSR, et al.Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods, 2003; 283(1–2):141–153; doi: 10.1016/j.jim.2003.09.001
21.
BarabasS, SpindlerT, KienerR, et al.An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol, 2017; 18(1):14; doi: 10.1186/s12865-017-0195-y
22.
ZhangW, CaspellR, KarulinAY, et al.ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring—Even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol, 2009; 6(4):227–234; doi: 10.3109/15476910903317546
23.
MäkitaloB, AnderssonM, AreströmI, et al.ELISpot and ELISA analysis of spontaneous, mitogen-induced and antigen-specific cytokine production in cynomolgus and rhesus macaques. J Immunol Methods, 2002; 270(1):85–97; doi: 10.1016/s0022-1759(02)00274-0
24.
LiaoW, LinJ-X, LeonardWJ. IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol, 2011; 23(5):598–604; doi: 10.1016/j.coi.2011.08.003
25.
WilliamsMA, TyznikAJ, BevanMJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature, 2006; 441(7095):890–893; doi: 10.1038/nature04790
26.
LaidlawBJ, CraftJE, KaechSM. The multifaceted role of CD4+ T cells in CD8+ T cell memory. Nat Rev Immunol, 2016; 16(2):102–111; doi: 10.1038/nri.2015.10
27.
HuangS. Non-genetic heterogeneity of cells in development: More than just noise. Development, 2009; 136(23):3853–3862; doi: 10.1242/dev.035139
28.
NicoletBP, GuislainA, WolkersMC. Combined single-cell measurement of cytokine mRNA and protein identifies T cells with persistent effector function. J Immunol, 2017; 198(2):962–970; doi: 10.4049/jimmunol.1601531
29.
FrentschM, StarkR, MatzmohrN, et al.CD40L expression permits CD8+ T cells to execute immunologic helper functions. Blood, 2013; 122(3):405–412; doi: 10.1182/blood-2013-02-483586
30.
NicoletBP, GuislainA, van AlphenFPJ, et al.CD29 identifies IFN-γ–producing human CD8+ T cells with an increased cytotoxic potential. Proc Natl Acad Sci U S A, 2020; 117(12):6686–6696; doi: 10.1073/pnas.1913940117
31.
PipkinME, SacksJA, Cruz-GuillotyF, et al.Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity, 2007; 32(1):79–90; doi: 10.1016/j.immuni.2009.11.012
32.
CurrierJR, KutaEG, TurkE, et al.A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods, 2002; 260(1–2):157–172; doi: 10.1016/s0022-1759(01)00535-x
33.
KuzminDA, ShutovaMV, JohnstonNR, et al.The clinical landscape for AAV gene therapies. Nat Rev Drug Discov, 2021; 20(3):173–174; doi: 10.1038/d41573-021-00017-7
34.
AuHKE, IsalanM, MielcarekM. Gene therapy advances: A meta-analysis of AAV usage in clinical settings. Front Med, 2022; 8:809118; doi: 10.3389/fmed.2021.809118
35.
NamH-J. Structure of adeno-associated virus serotype 8. 2008; doi: 10.2210/pdb2qa0/pdb
36.
DiMattiaMA, NamH-J, VlietKV, et al.Structural characterization of adeno-associated virus serotype 9. 2012; doi: 10.2210/pdb3ux1/pdb
37.
GorovitsB, AzadehM, BuchlisG, et al.Evaluation of cellular immune response to adeno-associated virus-based gene therapy. AAPS J, 2023; 25(3):47; doi: 10.1208/s12248-023-00814-5
38.
YangF, PattonK, KasprzykT, et al.Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates. Gene Ther, 2022; 29(1–2):41–54; doi: 10.1038/s41434-020-00214-w
39.
SlotaM, LimJ-B, DangY, et al.ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines, 2011; 10(3):299–306; doi: 10.1586/erv.10.169
40.
SabatinoDE, MingozziF, HuiDJ, et al.Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther, 2005; 12(6):1023–1033; doi: 10.1016/j.ymthe.2005.09.009
41.
SchillerA, ZhangT, LiR, et al.A positive control for detection of functional CD4 T cells in PBMC: The CPI pool. Cells, 2017; 6(4):47; doi: 10.3390/cells6040047
42.
LehmannAA, RechePA, ZhangT, et al.CERI, CEFX, and CPI: Largely improved positive controls for testing antigen-specific T cell function in PBMC compared to CEF. Cells, 2021; 10(2):248; doi: 10.3390/cells10020248
43.
MwauM, McMichaelAJ, HankeT. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses, 2002; 18(9):611–618; doi: 10.1089/088922202760019301
44.
PattonKS, HarrisonMT, LongBR, et al.Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method. Mol Ther Methods Clin Dev, 2021; 22:183–195; doi: 10.1016/j.omtm.2021.05.012
45.
SundararamanS, KarulinAY, AnsariT, et al.High reproducibility of ELISPOT counts from nine different laboratories. Cells, 2015; 4(1):21–39; doi: 10.3390/cells4010021
46.
MahnkeYD, BrodieTM, SallustoF, et al.The who's who of T-cell differentiation: Human memory T-cell subsets. Eur J Immunol, 2013; 43(11):2797–2809; doi: 10.1002/eji.201343751
47.
BoutinS, MonteilhetV, VeronP, et al.Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther, 2010; 21(6):704–712; doi: 10.1089/hum.2009.182
48.
BingSJ, JustesenS, WuWW, et al.Differential T cell immune responses to deamidated adeno-associated virus vector. Mol Ther Methods Clin Dev, 2022; 24:255–267; doi: 10.1016/j.omtm.2022.01.005
49.
Brito-SierraCA, LannanMB, SiegelRW, et al.The HLA class-II immunopeptidomes of AAV capsids proteins. Front Immunol, 2022; 13:1067399; doi: 10.3389/fimmu.2022.1067399
50.
MingozziF, MausMV, HuiDJ, et al.CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat Med, 2007; 13(4):419–422; doi: 10.1038/nm1549
51.
MingozziF, HighKA. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood, 2013; 122(1):23–36; doi: 10.1182/blood-2013-01-306647
52.
CaoL, LedeboerA, PanY, et al.Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials. Gene Ther, 2023; 30(1–2):150–159; doi: 10.1038/s41434-022-00353-2
53.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12(3):342–347; doi: 10.1038/nm1358
54.
MajowiczA, NijmeijerB, LampenMH, et al.Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs. Mol Ther Methods Clin Dev, 2019; 14:27–36; doi: 10.1016/j.omtm.2019.05.009
55.
MingozziF, ChenY, EdmonsonSC, et al.Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther, 2013; 20(4):417–424; doi: 10.1038/gt.2012.55
56.
GreenbergB, ButlerJ, FelkerGM, et al.Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther, 2016; 23(3):313–319; doi: 10.1038/gt.2015.109
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
